Ultragenyx Pharmaceutical (RARE) Expected to Announce Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.30) per share and revenue of $199.5960 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 13, 2026 at 4:00 PM ET.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The business had revenue of $159.93 million for the quarter, compared to analysts’ expectations of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.40) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Down 0.4%

Shares of RARE opened at $24.69 on Thursday. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -4.16 and a beta of 0.16. Ultragenyx Pharmaceutical has a 52-week low of $18.41 and a 52-week high of $46.50. The stock has a 50 day moving average price of $28.52 and a 200 day moving average price of $29.93.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Long‑term UX111 gene therapy data and regulatory progress — Ultragenyx published up to 8.5 years of follow‑up showing sustained, meaningful clinical benefit for UX111 (rebisufligene etisparvovec) in MPS IIIA and said it resubmitted the BLA to the U.S. FDA in January 2026 with an expected review period of up to six months. This materially improves the odds of near‑term regulatory clarity and eventual commercial upside if approved. Ultragenyx announces positive longer-term UX111 data
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a “buy” rating and a $60 price target, highlighting upside (~+143% vs. current levels) and giving investors a bullish valuation benchmark to weigh against recent weakness. HC Wainwright rating coverage
• Neutral Sentiment: Insider selling by the CFO — CFO Howard Horn sold 3,061 shares (~$72k) on Feb 2; this reduces his stake by ~3.3% but leaves substantial remaining ownership. Small dollar amount relative to market cap suggests limited direct financial implication, though markets sometimes interpret insider sales as a weak signal. CFO insider sale details
• Negative Sentiment: Class action filings and investigations — Robbins Geller Rudman & Dowd announced a proposed class action covering purchases from Aug 3, 2023 to Dec 26, 2025, alleging securities law violations. Litigation risk can increase volatility, potential legal costs, and management distraction. RGRD class action notice
• Negative Sentiment: Additional securities‑fraud notices — Robbins LLP issued an investor notice about a related securities class action, signaling multiple firms are investigating/filing claims; this reinforces legal risk and could pressure sentiment until resolved. Robbins LLP investor notice
• Negative Sentiment: Pomerantz investigation — Pomerantz LLP is also investigating claims on behalf of Ultragenyx investors, adding to the number of law firms reviewing potential litigation matters; more filings or consolidation of suits could follow. Pomerantz investigation notice

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $23.56, for a total value of $72,117.16. Following the sale, the chief financial officer directly owned 88,935 shares in the company, valued at $2,095,308.60. The trade was a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 6,227 shares of company stock valued at $187,126. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the company. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $39,000. Jacobs Levy Equity Management Inc. boosted its position in Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after purchasing an additional 1,864,164 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Ultragenyx Pharmaceutical by 2.0% in the third quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 534 shares during the last quarter. Voloridge Investment Management LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $14,516,000. Finally, Vestal Point Capital LP purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $22,560,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RARE. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Jefferies Financial Group cut their target price on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Leerink Partners decreased their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Finally, Robert W. Baird dropped their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.29.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.